Administer barbiturates with caution in clients with hepatic damage and at diminished doses in the beginning; barbiturates really should not be administered to patients displaying the premonitory signs of hepatic comapentobarbital will lower the level or outcome of acalabrutinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/